Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Sanchorawala V, et al. Among authors: barlogie b. Bone Marrow Transplant. 2013 Nov;48(12):1537-42. doi: 10.1038/bmt.2013.98. Epub 2013 Jul 15. Bone Marrow Transplant. 2013. PMID: 23852321 Free PMC article. Clinical Trial.
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F. Jethava Y, et al. Among authors: barlogie b. Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64. Blood Cancer J. 2016. PMID: 27471869 Free PMC article. Clinical Trial.
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Lee CK, et al. Among authors: barlogie b. Bone Marrow Transplant. 2002 Dec;30(12):873-8. doi: 10.1038/sj.bmt.1703715. Bone Marrow Transplant. 2002. PMID: 12476279
Suppression of abnormal karyotype predicts superior survival in multiple myeloma.
Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B. Arzoumanian V, et al. Among authors: barlogie b. Leukemia. 2008 Apr;22(4):850-5. doi: 10.1038/sj.leu.2405091. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200039 Free PMC article.
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B. Pineda-Roman M, et al. Among authors: barlogie b. Leukemia. 2008 Jul;22(7):1419-27. doi: 10.1038/leu.2008.99. Epub 2008 Apr 24. Leukemia. 2008. PMID: 18432260 Free PMC article. Clinical Trial.
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Usmani SZ, Zhang Q, Stratton K, Qu P, Yaccoby S, Hansen E, Steward D, Panozzo S, Petty N, Hoering A, Waheed S, Van Rhee F, Crowley J, Barlogie B. Usmani SZ, et al. Among authors: barlogie b. Leukemia. 2014 Dec;28(12):2413-5. doi: 10.1038/leu.2014.248. Epub 2014 Aug 25. Leukemia. 2014. PMID: 25151956 Clinical Trial. No abstract available.
695 results